CF Incidence, Prevalence and Survival

62

description

CF Incidence, Prevalence and Survival. Carrier rate of 1 in 25 Incidence of 1 in 2,500 live births By 2002 the number of adult patients will equal or exceed the number of children (Elborn et al 1991) Carrier screening may influence numbers (Cunningham & Marshall 1998). - PowerPoint PPT Presentation

Transcript of CF Incidence, Prevalence and Survival

Page 1: CF Incidence, Prevalence and Survival
Page 2: CF Incidence, Prevalence and Survival
Page 3: CF Incidence, Prevalence and Survival
Page 4: CF Incidence, Prevalence and Survival
Page 5: CF Incidence, Prevalence and Survival
Page 6: CF Incidence, Prevalence and Survival
Page 7: CF Incidence, Prevalence and Survival
Page 8: CF Incidence, Prevalence and Survival
Page 9: CF Incidence, Prevalence and Survival
Page 10: CF Incidence, Prevalence and Survival
Page 11: CF Incidence, Prevalence and Survival
Page 12: CF Incidence, Prevalence and Survival
Page 13: CF Incidence, Prevalence and Survival
Page 14: CF Incidence, Prevalence and Survival
Page 15: CF Incidence, Prevalence and Survival
Page 16: CF Incidence, Prevalence and Survival
Page 17: CF Incidence, Prevalence and Survival
Page 18: CF Incidence, Prevalence and Survival
Page 19: CF Incidence, Prevalence and Survival
Page 20: CF Incidence, Prevalence and Survival
Page 21: CF Incidence, Prevalence and Survival

CF Incidence, Prevalence and Survival

• Carrier rate of 1 in 25

• Incidence of 1 in 2,500 live births

• By 2002 the number of adult patients will equal or exceed the number of children (Elborn et al 1991)

• Carrier screening may influence numbers (Cunningham & Marshall 1998)

Page 22: CF Incidence, Prevalence and Survival

• Survival is now predicted to be 40 years for those patients born in the 1990’s

Page 23: CF Incidence, Prevalence and Survival

Caseload (annual report 4/00 - 3/01)

• 36 patients registered

• 3 patients on active transplant list

• 3 patients not suitable for transplant

• 2 deaths

Page 24: CF Incidence, Prevalence and Survival
Page 25: CF Incidence, Prevalence and Survival
Page 26: CF Incidence, Prevalence and Survival
Page 27: CF Incidence, Prevalence and Survival
Page 28: CF Incidence, Prevalence and Survival
Page 29: CF Incidence, Prevalence and Survival

Case Study

• Diagnosed at 10 months with steatorrhea and LRTI

• Stable until 13 when she required increasingly frequent IV’s

• Pregnancy 1996 - TOP @ 16 weeks• Since 1998 she has suffered more frequent

exacerbations and now requires IV’s monthly

Page 30: CF Incidence, Prevalence and Survival

• Oxygen dependent

• Abnormal liver function

• Occasional episodes of DIOS

• Button gastrostomy inserted

• Transplant assessment Dec 2000

• Overnight BiPAP from June 2001

• Difficulty in controlling pain and nausea

Page 31: CF Incidence, Prevalence and Survival

• Bi-lateral lung transplant Sept 2001

Page 32: CF Incidence, Prevalence and Survival

Specialities Involved

• Respiratory

• Gastro-Intestinal

• Obs & Gynae

• GP/DN

• Surgery

• Transplant team

• Child & Family Psychiatry

Page 33: CF Incidence, Prevalence and Survival
Page 34: CF Incidence, Prevalence and Survival
Page 35: CF Incidence, Prevalence and Survival
Page 36: CF Incidence, Prevalence and Survival
Page 37: CF Incidence, Prevalence and Survival
Page 38: CF Incidence, Prevalence and Survival
Page 39: CF Incidence, Prevalence and Survival
Page 40: CF Incidence, Prevalence and Survival
Page 41: CF Incidence, Prevalence and Survival

Diabetic Control

• Patients with CFRD - 5

• Glucose Intolerant patients - 2

Page 42: CF Incidence, Prevalence and Survival

Intravenous Antibiotics

• 206 in-patient days

• 894 out-patient days

Page 43: CF Incidence, Prevalence and Survival

Home Visits

IV's

TIVAD

Support

P.Care

Other

• Total number - 400

• Mileage - 11809

Page 44: CF Incidence, Prevalence and Survival

Quality Issues

• Performance indicator tool for home IV’s

• Risk assessment of patients carrying out home IV’s

• Introduction of segregated clinics from Jan 01

Page 45: CF Incidence, Prevalence and Survival

Role of CFCNS

• “National consensus standards for the nursing management of cystic fibrosis” march 2001

Page 46: CF Incidence, Prevalence and Survival

Responsibilities

• Advocacy

• Clinical Management

• Support and Advice

• Education for patient, families and carers

• Education, research and management

Page 47: CF Incidence, Prevalence and Survival

• Psychology

• Dietetics

• Physiotherapy & Community physio

• Social work

• Dr Paterson (bone densitometry)

• Pain clinic

• Rheumatology

Page 48: CF Incidence, Prevalence and Survival
Page 49: CF Incidence, Prevalence and Survival
Page 50: CF Incidence, Prevalence and Survival
Page 51: CF Incidence, Prevalence and Survival
Page 52: CF Incidence, Prevalence and Survival

CYSTIC FIBROSIS

Mags Pogson CFCNS

Lawrie MacDougall CFCNS

Page 53: CF Incidence, Prevalence and Survival

Physiological and Radiological Characterisation of Patients With

COPD in Primary Care

• 110 patients aged 40-80• Acute exacerbation of COPD diagnosed by GP• HRCT chest and physiological assessment when

stable @ 2 months later

– O’Brien et al Thorax 2000;55:635-42

Page 54: CF Incidence, Prevalence and Survival

Physiological and Radiological Characterisation of Patients With

COPD in Primary Care

• Wide range of impairment of FEV1

• Only 5% of patients had a significant bronchodilator response

• Emphysema present in 51% of patients

• Bronchiectasis present in 29% of patients

– O’Brien et al Thorax 2000;55:635-42

Page 55: CF Incidence, Prevalence and Survival
Page 56: CF Incidence, Prevalence and Survival
Page 57: CF Incidence, Prevalence and Survival
Page 58: CF Incidence, Prevalence and Survival
Page 59: CF Incidence, Prevalence and Survival
Page 60: CF Incidence, Prevalence and Survival
Page 61: CF Incidence, Prevalence and Survival
Page 62: CF Incidence, Prevalence and Survival